News & Blogs

Jack Rowing: Profitable Healthcare Activism

Politics is filled with hot-button issues. Polarizing topics are routinely brought up on twitter, in congressional meetings, and during rose garden speeches. Abortion, guns, and policing are all on the table and docket. This is in large part due to activists who make a living on keeping issues in the spotlight to enact change. It has become a highly lucrative field. Recent news reports of BLM activists making millions of dollars through fraud, and buying…

Learn More

AARP Overcharges Seniors to Raise Its Bottom Line

In a recent exposé, the Daily Caller News Foundation details how “AARP Rakes in Record Profits Selling Brand Royalties While Overcharging Members.” While the organization bills itself as a scrappy senior advocacy group, its recent financial disclosures—as well as its own admission in court—cast serious doubt on whether it acts “with the interest of its members in mind.” The Daily Caller took a deep dive into AARP’s money tree and the resulting conflict of interest.…

Learn More

Jon Decker: Why Build Back Better’s prescription price controls are a bad idea

Joe Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force — AARP — and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If…

Learn More

On Build Back Better and Gasoline: Why Price Controls Are Always A Bad Idea

Biden’s “Build Back Better” nonsense is getting a boost from an extremely powerful and well-funded lobbying force—the AARP—and it’s time for us to call them out on it. The so-called “seniors advocacy organization” has been pushing hard for the passage of Biden’s massive, inflation-inducing spending bill. Why? Because the House version of the bill would have the federal government set the price of prescription drugs under the guise of “negotiation.” If the bill were enacted,…

Learn More

Newt Gingrich: Democrats say they are the party of science but their drug price plans tell a different story

The Democrats like to present themselves as the party of science, but two recent announcements show just how ignorant they are about how science moves from the lab into our medicine cabinet. The first announcement was results from Pfizer’s clinical trial of its new anti-viral treatment for COVID-19. The treatment reduced hospital admissions in high-risk individuals by a stunning 90 percent compared to those receiving a placebo. Even more remarkably, not a single person receiving…

Learn More

During this Year’s Medicare Open Enrollment, Don’t Assume AARP Has Your Best Interests in Mind

Millions of seniors are considering their options during this year’s Medicare open enrollment period, which is underway through December 7. Before making this important decision, though, seniors should do their research. This is especially true if they are considering an AARP-promoted Medicare Advantage or Medigap plan. Currently, AARP maintains an exclusive relationship with UnitedHealthcare (UHC)—meaning they only sell plans carried by that insurance giant. However, these plans are overpriced when purchased through AARP. So why,…

Learn More

Richard Berman: Drug pricing proposal is another exercise in Washington short-sightedness

Policymakers often create long-term harm while chasing short-term rewards. Running up the national debt creates electoral goodwill now because people like free stuff. In the long run, debt service payments will increasingly crowd out other spending priorities. Eventually, the music stops. The feedback loop created by guaranteed government-backed college loans and subsidies is similar. Although net tuition costs are temporarily reduced, the guarantee of student aid incentivizes universities to raise the price of admission higher,…

Learn More

Phil Kerpen: Drug Price Controls Would Hurt Seniors

The latest iteration of Build Back Better – the president’s multi-trillion-dollar tax-and-spending binge that has been stalled in Congress all year – purports to reduce the cost of prescription drugs via negotiation. Medicare prescription drug plans already negotiate prices aggressively. As Obama’s CBO director Doug Elmendorf explained back in 2009: “additional authority to negotiate for lower drug prices would have little, if any, effect on prices for the same reason that my predecessors have explained,…

Learn More